chrisvoncsefalvay/vaers-outcomes huggingface dataset:
The day after my 3rd dose I experienced left arm pain and a new extreme pain in all of my joints.  With my first dose I had similar left arm pain, but with the second dose the left arm pain had been minimal.  However, I don't remember ever feeling joint pain with my first two doses.  Days 3 to 5 after my 3rd dose, the arm and joint pain slowly subsided and completely went away.  However, in the weeks since on random days like today I will experience pain in my left arm at the shot location, my wrist joints, finger joints, and occasionally other random joints as well and those areas usually feel warmer than normal.
This spontaneous report was received from a nurse regarding 3 unknown age infant patients of unknown gender. The patient's medical history, concurrent conditions, concomitant medications and drug reactions/allergies were not provided. On 20-JUN-2018, the "3 infant patients" were administered adult doses of RECOMBIVAX lot# R006746 and 09-NOV-2020 expiration date for prophylaxis (strength, frequency and route of administration were not reported). No adverse effects were reported. No product quality complain was reported.
Swollen deltoid left down to (red) elbow. Warm to touch, no fever, little pain.
Information has been received regarding a case in liitgation concerning a male child who, for the first two years of his life, was vaccinated with injections containing then "dangerous and highly toxic" mercury based preservative Thimerosal. The alleged result of these vaccinations is that the patient now suffers from, and allegedly in the future will continue to suffer from the toxic neurological effects of mercury poisoning. Immunization records were received as FOLLOW-UP information. It was reported that the patient was vaccinated with Recombivax (lot # given not valid) given in the right anterior thigh on 11/21/96, 01/29/97 and 10/01/97. Concomitant therapy included MMR (lot # not valid), ACTHib/DTP, given in the right anterior thigh on 11/21/96 and in the left anterior thigh on 01/29/97 and 03/25/97, Tripedia, given in left deltoid on 03/31/98, Orimune , given 11/21/96, 01/29/97 and 03/25/97. ACtHib given in the left deltoid on 12/24/97. Upon internal review toxic neurological effect and mercury poisoning were determined to be other important medical events. No further information is available. A 15-day follow up report received 05/20/2003 adds: It was also noted that the pt was born via vaginal delivery at 38 weeks weighing 5lb 5oz. There were no birth complications. It was also noted that the pt's father has the thalassemia trait. Follow up info received on 05/01/2002 reported that the pt received injections of vaccines that have been alleged to contain thimerosal on the following dates: 11/21/1996, 01/29/1997, 03/25/1997, 10/01/1997, 12/24/1997, 03/31/1998/ 04/29/1999 and 10/09/2000. Upon internal review toxic neurologic effect and mercury poisoning were determined to be other important medical events. No further info is available. A copy of the pt's medical record is available upon request.
A few minutes after administration at 6:10 pm husband rushed to the pharmacy (6:15pm) to let me know his wife is getting dizzy. I rushed out with the IMZ cart patient was not responsive  with open eyes, slightly rolled eyes and was not following, She said "felt like blacked out for a sec and woke up feeling really hot and sweaty".  She sat down for about 30 minutes she was feeling fine and was talking to everyone normally. At 7:20 pm she came back to the pharmacy to let me know she is still doing fine.
hit by a car and hospitalized for a week; arm soreness; This spontaneous case was reported by an other health care professional and describes the occurrence of ROAD TRAFFIC ACCIDENT (hit by a car and hospitalized for a week) in a 75-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 029L20A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     No Medical History information was reported.    On 17-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 17-Feb-2021, the patient experienced PAIN IN EXTREMITY (arm soreness). In March 2021, the patient experienced ROAD TRAFFIC ACCIDENT (hit by a car and hospitalized for a week) (seriousness criterion hospitalization). The patient was hospitalized for 7 days due to ROAD TRAFFIC ACCIDENT. At the time of the report, ROAD TRAFFIC ACCIDENT (hit by a car and hospitalized for a week) and PAIN IN EXTREMITY (arm soreness) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On an unknown date, Antibody test: had testing showing antibodies that had persisted Had testing showing antibodies that had persisted up to this point..     The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   No concomitant drugs were reported.  Patient received the first dose of the moderna covid-19 vaccine by intramuscular injection on 17FEB2021 (lot number 029L20A, expiration date 30JUN2021). Patient had a little bit of arm soreness after receiving the vaccine but did not take any treatments for the symptoms. Prior to receiving the second dose of the vaccine patient was hit by a car and hospitalized for a week. Patient was placed on steroids as part of this hospitalization. The doctors were now recommending that the patient should receive additional doses of the Moderna vaccine. Patient had not received a second dose at that time, but had testing showing antibodies that have persisted up to this point.  Company comment: This case concerns a 75-year-old female patient with no medical history reported, who experienced the unexpected, serious (hospitalization) event of road traffic accident. The event occurred approximately 1 month after the first dose of mRNA-1273. The event has been assessed as not related to mRNA-1273 due to the nature of the event. The benefit-risk relationship of mRNA-1273 is not affected by this report.; Sender's Comments: This case concerns a 75-year-old female patient with no medical history reported, who experienced the unexpected, serious (hospitalization) event of road traffic accident. The event occurred approximately 1 month after the first dose of mRNA-1273. The event has been assessed as not related to mRNA-1273 due to the nature of the event. The benefit-risk relationship of mRNA-1273 is not affected by this report.
10 minutes after injection: patient notified RN that he was feeling warm and his arm was getting really red; erythemic area with short well defined slightly raised border.
temperature excursion for ROTATEQ; This spontaneous report as received from a physician refers to a patient of unknown age and gender. The patient's concurrent conditions, medical history and concomitant therapies were not reported.   On 26-MAY-2021, the patient's were vaccinated with inappropriate stored dose of rotavirus vaccine, live, oral, pentavalent (ROTATEQ), orally lot# 1691299 and expiration date of 21-DEC-2021 (strength and dose were not provided) for prophylaxis. The temperature excursions were the following: Temperature (0.7°C) for 54 hours and 45 minutes; (8.6°C) for 47 hours 15 minutes. There was no previous temperature excursion. The call was registered due to a data logger. The adverse event report was filled precautionary.   This is one of several reports received from the same reporter
Chills; Body aches; Feel like flu; Tired; This is a spontaneous report from a contactable consumer, the patient. A 52-year-old male patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EN6203) via an unspecified route of administration in the left arm on 11Mar2021 at 15:00(at the age of 52-years-old) as a single dose for COVID-19 immunisation. The patient had no relevant medical history. The patient had no known allergies to medications, food or other products.  Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. The patient had not received any concomitant medication. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EI3247) via an unspecified route of administration in the left arm on 19Feb2021 at 15:10 (at the age of 52-years-old) as a single dose for COVID-19 immunisation. On 12Mar2021 at 02:30 the patient experienced chills, body aches, felt like flu and tired. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Therapeutic measures were not taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19.  The clinical outcome of the event chills was resolved on 13Mar2021 at 07:15. The clinical outcome of the events body aches, felt like flu and tired was not resolved at the time of this report.  No follow-up attempts are needed. No further information is expected.
10 minutes after vaccine was administered, patient complained of a severe dry mouth.  Patient reported no trouble breathing and slight trouble swallowing due to the dryness of her mouth.  Patient was given Benadryl at a 25mg dose and watched for 45 minutes with no additional signs of a reaction and the dry mouth starting to subside.
Initial information received from a consumer on 20-Feb-2018. This case involves a 57-year-old female patient who was vaccinated with FLU VACCINE (Batch number, expiry date, dose, dose series route and site of administration were not reported) on an unknown date. The patient also received 150 mg injection of ALIROCUMAB (PRALUENT) from Jul-2016. The patient's medical history and concomitant medication was not reported. On an unknown date, following vaccination the patient experienced allergic reaction to Flu vaccine and hence visited ER. Patient's lab test was not reported. The patient had been treated with steroids. Outcome of event was reported as unknown. The company assessed the causal relationship with FLU VACCINE as possible. List of documents held by sender: none.
Probably Guillen Barre onset 11/26/02. Upper respiratroy tract infection approximately 1 week prior to admit, was febrile illness with sore throat. Resolved for 3-4 days prior to onset of symptoms. 11/23-24 normal health. 11/26 upper extremity tingling, felt weak. 11/27 upper extremity tingling, extremely weak, lots of phlegm, admit to hospital with presumed Guillen Barre. 11/28 intubated secondary to unable to protect airway. 11/29 significantly weaker. 11/30 communicates with notds, blinks, able to move arms, legs, some grip. Hypertension becoming a problem. 12/3 hypertension still a problem, probably secondary to agitation, as blood pressure decreases significantly with versed and morphine. 11/27 IVIG 400 mg/kg/day x 5 days started. 12/3 hypertensive meds nitropaste half inch q6h, zestril 80mg qday, lopressor 100mg po bid, clonidine .2mg po qday, Morphine and versed IV prn. Still paralyzed, intubated, unable to eat = tube feedings, DC to long term nursing home. Follow up states: Pt has not recovered. Still paralized, intubated, unable to eat- tube feedings, DC to long term nursing home. Annual follow up on 12/24/03: "It is unknown if the vaccine recipient has recovered from the adverse events that were reported for this vaccination."
Temperature 104 degrees F, severe headache, 6 inch arm reaction w/ erythema (? Arthus reaction - not true hemorrhage though), nausea, anorexia, malaise, body aches. Still febrile at 101 degrees on 3/17 and large arm reaction still visible.
Swelling, pain with mark in site, swelling and pain above clavicle area. Symptoms stayed for four days. Treated with antihistamines.
following 3rd dose of vax pt exp n,v, lightheadness, dizziness; bitten by stray cat; seen by MD; MD did not think sx relater to vax;
bad acid reflux; raised blood sugar; nausea; This spontaneous case was reported by a consumer and describes the occurrence of GASTROOESOPHAGEAL REFLUX DISEASE (bad acid reflux), BLOOD GLUCOSE INCREASED (raised blood sugar) and NAUSEA (nausea) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient experienced GASTROOESOPHAGEAL REFLUX DISEASE (bad acid reflux), BLOOD GLUCOSE INCREASED (raised blood sugar) and NAUSEA (nausea). At the time of the report, GASTROOESOPHAGEAL REFLUX DISEASE (bad acid reflux), BLOOD GLUCOSE INCREASED (raised blood sugar) and NAUSEA (nausea) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       Patient Wondering if she could take Zofran for side effects such as nausea
Feeling unwell; Fatigue; This is a spontaneous report from a contactable consumer (Pfizer employee). An elderly non-pregnant female patient of unknown age received BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via intramuscular route of administration in the left arm on 02Sep2021 at 10:00 as a single dose for COVID-19 immunisation. It was unknown if the patient had any medical history and known allergies. Prior to the vaccination, it was unknown whether the patient was diagnosed with COVID-19. It was unknown whether the patient had received any other vaccines within four weeks prior to the COVID vaccine. It was unknown if the patient received any concomitant medications. On 03Sep2021, the patient was feeling unwell and experienced fatigue. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Since the vaccination, it was unknown whether the patient had been tested for COVID-19. Therapeutic measures were not taken as a result of the events. The clinical outcome of the events feeling unwell and fatigue was resolving at the time of this report.  The lot number for BNT162b2 was not provided and will be requested during follow up.
2nd dose after 45 days; This spontaneous case was reported by a consumer and describes the occurrence of INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (2nd dose after 45 days) in a male patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.   On an unknown date, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On an unknown date, the patient experienced INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (2nd dose after 45 days). At the time of the report, INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (2nd dose after 45 days) had resolved.            No concomitant medication was reported by the reporter. No treatment information was provided.
Received Fluzone on 11/3/06 in AM by 6 PM same day noticed left side of face droopy. Went to ER Saturday 11/4/06 in afternoon. DX with Bells Palsy. Still droopy at this time 11/9/06. DC DX: Bell's Palsy in ER on 11/4/06 Seen in ER for facial assymetry on right. Difficulty closing left eye. CT head: evaluation of posterior fossa was mildly degraded by streak artifact. The fourth ventricle is midline without mass impression. Evaluation of suprtentorial brain revealed evidence of coritcal mild atrophy. No ventriculomegaly. No mass or midline shift. No extraazxial fluid collection. No acute major territorial infarct or intracranial hemorrhage
pt recv vax 1FEB95 & exp abd cramps & vaginal bleeding (spotting) which required an ER or MD visit;MD intended to conduct a sonogram;
Within a few hours of each of the 1st three doses of the Anthrax vaccine, on 1/15/99, 2/2/99 and 2/18/99 the pt experienced a severe caffeine high, inability to concentrate/function.
Like if someone was "twisting the muscle" / Can't do anything /Stop everything she's doing; Pain isalso getting sooner than later, more often than before, almost everyday; Pain in the middle of her upper arm, in the inside muscle; Second injection wasn't as painful as the first dose, but pain's still there; This spontaneous case was reported by a consumer and describes the occurrence of MOBILITY DECREASED (Like if someone was "twisting the muscle" / Can't do anything /Stop everything she's doing), CONDITION AGGRAVATED (Pain isalso getting sooner than later, more often than before, almost everyday), VACCINATION SITE PAIN (Second injection wasn't as painful as the first dose, but pain's still there) and MYALGIA (Pain in the middle of her upper arm, in the inside muscle) in a 71-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 206A21A) for COVID-19 vaccination.     No Medical History information was reported.    On 28-Mar-2021, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 28-Mar-2021, the patient experienced VACCINATION SITE PAIN (Second injection wasn't as painful as the first dose, but pain's still there). On an unknown date, the patient experienced MOBILITY DECREASED (Like if someone was "twisting the muscle" / Can't do anything /Stop everything she's doing) and MYALGIA (Pain in the middle of her upper arm, in the inside muscle). an unknown date, the patient experienced CONDITION AGGRAVATED (Pain isalso getting sooner than later, more often than before, almost everyday). At the time of the report, MOBILITY DECREASED (Like if someone was "twisting the muscle" / Can't do anything /Stop everything she's doing), CONDITION AGGRAVATED (Pain isalso getting sooner than later, more often than before, almost everyday) and MYALGIA (Pain in the middle of her upper arm, in the inside muscle) outcome was unknown and VACCINATION SITE PAIN (Second injection wasn't as painful as the first dose, but pain's still there) had not resolved.            The Patient stated that she has not taken any medication for the pain as it comes in short episodes and last a few seconds.   The patient stated that she consulted her Physician on 31 August 2021.  No concomitant product use was provided by the reporter.   This case was linked to MOD-2021-305083 (Patient Link).
This case was reported by a physician and described the occurrence of reaction to flu vaccination in an adult female subject who was vaccinated with seasonal influenza vaccine (manufacturer unspecified). On an unspecified date the subject received unspecified dose of seasonal influenza vaccine (unknown). At an unspecified time after vaccination with seasonal influenza vaccine, the subject experienced reaction to flu vaccination. The physician inquired about down feathers allergy and the flu vaccine. It was reported that the subject, who is the mother of the physician's current client, had a "bad reaction to the flu vaccine" in the past; details regarding the brand of vaccine and date were unknown. The physician reported that the subject thought because she is "allergic to down feathers and the flu vaccines are made from eggs". The physician had no further information because the details regarding the vaccination were unknown and the subject is not his patient. At the time of reporting the outcome of the event was unspecified.
Swollen entire left leg to the point I can?t pull my left pant leg all the way up
Our medical clinic is part of the VFC program and one of our VFC refrigerators malfunctioned and created a too low temperature for vaccines to be viable. Patient received vaccination due to human error in not pulling the non-viable vaccines from refrigerator when it was reported that all non-viable vaccines were pulled correctly and transferred correctly. After speaking with all pharmaceutical companies regarding patient receiving non-viable vaccines, patient have been recalled and will received vaccine as soon as possible. Age of patient at time of event: 11 years 6 months.
The vial was initially stored in the refrigerator on 01-Sep-2022 and was administered on 28-Nov-2022; Caller would like to viability information because they had the wrong expiration date for the Covid-19 vaccine; No adverse event; Dose administered after 30-day Use By Date; This spontaneous case was reported by an other health care professional and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (Dose administered after 30-day Use By Date), PRODUCT STORAGE ERROR (The vial was initially stored in the refrigerator on 01-Sep-2022 and was administered on 28-Nov-2022), PRODUCT EXPIRATION DATE ISSUE (Caller would like to viability information because they had the wrong expiration date for the Covid-19 vaccine) and NO ADVERSE EVENT (No adverse event) in an 82-year-old male patient who received mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (batch no. AS7140C) for COVID-19 prophylaxis.     It was unknown if patient received any other vaccines in the 4 weeks prior to COVID-19 vaccine.     On 28-Nov-2022, the patient received dose of mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (unknown route) 1 dosage form. On 28-Nov-2022,  after starting mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)), the patient experienced EXPIRED PRODUCT ADMINISTERED (Dose administered after 30-day Use By Date). On an unknown date, the patient experienced PRODUCT STORAGE ERROR (The vial was initially stored in the refrigerator on 01-Sep-2022 and was administered on 28-Nov-2022), PRODUCT EXPIRATION DATE ISSUE (Caller would like to viability information because they had the wrong expiration date for the Covid-19 vaccine) and NO ADVERSE EVENT (No adverse event). At the time of the report, EXPIRED PRODUCT ADMINISTERED (Dose administered after 30-day Use By Date), PRODUCT STORAGE ERROR (The vial was initially stored in the refrigerator on 01-Sep-2022 and was administered on 28-Nov-2022), PRODUCT EXPIRATION DATE ISSUE (Caller would like to viability information because they had the wrong expiration date for the Covid-19 vaccine) and NO ADVERSE EVENT (No adverse event) outcome was unknown.        For mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (Unknown), the reporter considered NO ADVERSE EVENT (No adverse event) to be not related. No further causality assessments were provided for EXPIRED PRODUCT ADMINISTERED (Dose administered after 30-day Use By Date), PRODUCT STORAGE ERROR (The vial was initially stored in the refrigerator on 01-Sep-2022 and was administered on 28-Nov-2022) and PRODUCT EXPIRATION DATE ISSUE (Caller would like to viability information because they had the wrong expiration date for the Covid-19 vaccine).    No concomitant information was reported. Suspect product dosage text was reported as unknown. The one dose vial did not underwent any temperature excursions. The vial was 01-Oct-2022. No treatment information was provided.
2 hrs folllowing administration of Influenza vax, pt exp edema, pain, & erythema @ inject site; Area affected was approx 14 mm in diameter;